AI Agent Trust Requirements in Healthcare vs. Finance: A Comparative Analysis

When a senior AI engineer moves from a healthcare company to a financial services firm, or vice versa, they frequently describe the experience as learning a different language. Both domains use AI. Both have stringent trust requirements. Both have experienced high-profile AI failures that shaped the regulatory landscape. But the specific requirements, the language used to express them, the regulatory bodies that enforce them, the liability structures that create consequences, and the cultural norms around risk tolerance are sufficiently different that expertise in one domain transfers only partially to the other.

This comparative analysis exists to build the translation layer. By systematically comparing AI agent trust requirements across eight dimensions in healthcare and financial services, we create a framework that practitioners can use regardless of which domain they are entering, and that organizations managing AI agent deployments across both domains can use to understand where requirements converge and where they diverge.

The comparison is not purely theoretical. Both domains have deployed AI agents at scale and experienced failures. The regulatory frameworks in both domains were shaped partly by those failures. Understanding both domains together produces insights that neither produces alone.

TL;DR

• Healthcare and financial services share a common trust foundation (behavioral evidence, human oversight, audit trails) but differ significantly in their specific requirements for data governance, liability, adversarial threat models, and certification paths.
• Healthcare prioritizes patient safety above all other concerns — a risk that does not exist in financial services but shapes every governance decision in clinical AI.
• Financial services faces a unique concern — market manipulation — that has no healthcare analog, and requires real-time oversight that healthcare does not typically require.
• The eight dimensions compared: regulatory framework, liability structure, data governance, behavioral evaluation, oversight requirements, adversarial threat models, incident response, certification paths.
• Organizations deploying AI agents across both domains need domain-specific behavioral pacts and context-specific trust scoring, not a one-size-fits-all approach.
• Armalo's domain-specific pact templates and context-aware trust scoring provide differentiated infrastructure for both domains.

Comparison Dimension 1: Regulatory Framework

Healthcare

The primary US regulatory framework for AI agents in healthcare is a three-body regime:

FDA (Food and Drug Administration) regulates AI used as Software as a Medical Device (SaMD). The SaMD framework applies when AI influences clinical decisions — diagnosis, treatment recommendations, care pathway determination. AI agents that support these functions are typically SaMD and require either 510(k) clearance (substantially equivalent to an existing device) or De Novo authorization (for novel devices without predicate). The FDA's AI/ML-Based SaMD Action Plan (2021) introduced the concept of "predetermined change control plans" — allowing AI models to update without a new clearance submission if changes are within pre-specified parameters.

OCR (Office for Civil Rights, HHS) enforces HIPAA and HITECH Act compliance. AI agents processing protected health information (PHI) are covered entities or business associates under HIPAA, subject to Privacy Rule (limitations on PHI use and disclosure), Security Rule (technical, administrative, and physical safeguards), and Breach Notification Rule (notification requirements for PHI breaches).

ONC (Office of the National Coordinator for Health Information Technology) has authority over health IT standards and interoperability. AI agents interacting with electronic health records must meet certification criteria under the 21st Century Cures Act's information blocking provisions.

EU equivalent: MDR (Medical Device Regulation) for SaMD classification; GDPR for health data processing; combined with the AI Act for high-risk AI in healthcare.

Financial Services

Financial services has a denser, jurisdiction-dependent regulatory landscape:

SEC (Securities and Exchange Commission) regulates AI in investment advisory, market analysis, and securities trading. The SEC has issued guidance on the use of AI/ML in investment advice under the Investment Advisers Act, emphasizing that advisers using AI remain subject to fiduciary duty obligations regardless of whether the advice is AI-generated. The proposed Predictive Analytics rule (2023) would require advisers to evaluate AI systems for conflicts of interest.

FINRA (Financial Industry Regulatory Authority) oversees broker-dealers. FINRA's Regulatory Notice 20-38 and subsequent guidance require that AI systems used in customer interactions meet the same suitability requirements as human advisors. Robo-advisors and AI recommendation agents must be consistent with FINRA's suitability, Know-Your-Customer (KYC), and Best Interest obligations.

OCC (Office of the Comptroller of the Currency) and Federal Reserve regulate AI in banking activities including credit underwriting, fraud detection, and customer service for national banks. The Interagency Guidance on Model Risk Management (SR 11-7) — while predating modern LLM-based AI — is applied to AI models in banking and requires rigorous model validation.

CFPB (Consumer Financial Protection Bureau) has authority over consumer credit decisions. AI systems making or supporting credit decisions must comply with the Equal Credit Opportunity Act (ECOA) and Fair Housing Act (FHA) — requiring explainability of adverse action decisions in terms consumers can understand.

EU equivalent: MiFID II for investment services AI; DORA (Digital Operational Resilience Act) for ICT risk management; AI Act for high-risk credit and employment decisions.

Comparison

The regulatory landscape is denser in financial services but more technically specific in healthcare. Healthcare's FDA pathway creates a formal pre-market review process with specific technical requirements; financial services regulation is primarily principle-based (fiduciary duty, suitability), leaving significant discretion to regulated entities in how they implement AI. This creates different compliance challenges: healthcare faces more prescriptive technical requirements, while financial services faces more interpretive compliance uncertainty.

Comparison Dimension 2: Liability Structure

Healthcare

Clinical AI liability is primarily governed by medical malpractice law. The question in malpractice cases is whether the care provided met the standard of care. For AI-assisted clinical decisions, the emerging standard is that clinicians remain responsible for the final decision — AI is a tool, not a decision-maker, and the clinician's failure to exercise appropriate clinical judgment in the presence of AI assistance is a malpractice risk.

The standard-of-care question for AI assistance in healthcare is not yet fully settled. The argument that "a reasonable clinician would use AI assistance" and the counter-argument that "a reasonable clinician would not over-rely on AI assistance" will continue to be contested in litigation for years. The risk for AI developers is product liability for design defects in AI that systematically produces incorrect clinical guidance.

Key liability dynamic: The "learned intermediary" doctrine — which generally shields drug manufacturers from direct liability when prescribers (the intermediaries) make the final prescribing decision — may apply to clinical AI, shielding AI developers from direct liability for clinical decisions made by clinicians using their AI. This doctrine's application to AI is not yet established.

Financial Services

Financial services AI liability operates through multiple channels:

Fiduciary duty. Investment advisers and broker-dealers owe fiduciary duties to clients. AI recommendations that systematically favor the firm's interests over clients' interests create fiduciary duty claims. Unlike healthcare's learned intermediary defense, there is no comparable doctrine shielding AI developers from fiduciary duty claims in financial services — if the AI's recommendations are systematically conflicted, the firm bears the liability.

ECOA/FHA adverse action. Credit AI that systematically disadvantages protected classes creates claims under ECOA and FHA. These are strict liability provisions in the sense that discriminatory effect is sufficient — intent to discriminate is not required.

Market manipulation. AI agents that execute trades in patterns that constitute market manipulation — wash trading, spoofing, layering — create criminal and civil liability under securities law. This is the financial services liability risk with no healthcare analog.

Comparison: Healthcare liability is primarily filtered through the clinician relationship (learned intermediary-style) while financial services liability is more direct. Healthcare malpractice is fact-intensive and expensive to litigate; financial services regulatory penalties can be assessed more efficiently. Both domains face class action exposure for systematic AI failures.

Comparison Dimension 3: Data Governance

Healthcare

HIPAA defines 18 categories of PHI that constitute protected health information. AI agents processing any of these categories are subject to HIPAA's full compliance framework. Key requirements:

Minimum necessary standard. AI agents must access only the PHI necessary for the specific purpose. An agent analyzing lab results should not also access psychotherapy notes unless the specific task requires it.

De-identification. HIPAA provides two methods for de-identifying PHI: the Expert Determination method and the Safe Harbor method. AI agents working with de-identified data are not subject to HIPAA restrictions — but the de-identification must be technically robust. Re-identification attacks using LLM capabilities are an emerging concern.

Business Associate Agreements (BAAs). Any AI platform that accesses PHI on behalf of a covered entity must enter a BAA with the covered entity. BAAs specify the permitted uses of PHI, the required safeguards, and breach notification obligations. Cloud AI platforms used for healthcare applications must sign BAAs.

Right of Access. Patients have a right to access their health information. AI agents that generate records (clinical notes, AI-assisted diagnoses) create new records that may be subject to right-of-access requests.

Financial Services

Financial data governance is governed by multiple overlapping frameworks:

GLBA (Gramm-Leach-Bliley Act). Requires financial institutions to protect customers' nonpublic personal information (NPI) — defined broadly to include any personally identifiable financial information that is not publicly available. AI agents processing customer financial data must implement technical and organizational safeguards meeting GLBA requirements.

SOX (Sarbanes-Oxley Act). For public companies, SOX requires that AI systems affecting financial reporting have adequate internal controls. AI that influences financial statement preparation or disclosure is subject to SOX control requirements, including testing and auditing.

AML/KYC requirements. AI agents involved in customer onboarding or transaction monitoring must comply with Bank Secrecy Act (BSA) requirements for Anti-Money Laundering (AML) and Know Your Customer (KYC). AI models for AML/KYC must be validated, documented, and subject to ongoing model risk management.

Market data regulations. AI agents accessing material non-public information (MNPI) are subject to insider trading regulations. System controls must prevent AI agents from trading based on MNPI — a requirement that requires careful architectural design in AI agents with broad data access.

Comparison

Healthcare data governance is more procedurally specific (HIPAA's 18 categories, BAA requirements, minimum necessary standard) while financial services data governance is more principle-based (reasonable safeguards, appropriate controls). Healthcare's data governance is primarily protective; financial services adds the unique regulatory concern about information asymmetry (MNPI, insider trading) that has no healthcare parallel.

Comparison Dimension 4: Behavioral Evaluation

Healthcare

Clinical AI behavioral evaluation has been most significantly shaped by the FDA's SaMD framework and the growing literature on clinical AI safety. Key evaluation requirements:

Clinical validation. SaMD must demonstrate clinical validity in the intended use population. For AI agents supporting clinical decisions, this means demonstrating that the agent's recommendations are clinically appropriate across the relevant patient population, including under-represented subgroups.

Algorithmic bias evaluation. OCR and the FDA have both emphasized that clinical AI must be evaluated for performance disparities across demographic groups — race, sex, age, socioeconomic status. AI that performs well on majority populations but poorly on minority populations creates both clinical harm and legal exposure.

Failure mode analysis. Clinical AI evaluation should include systematic analysis of failure modes: what types of cases does the AI get wrong, and what are the clinical consequences of those errors? The FDA's guidance on SaMD encourages prospective analysis of failure modes rather than purely retrospective evaluation of accuracy metrics.

Real-world performance monitoring. The FDA's predetermined change control plan framework implicitly requires ongoing monitoring of real-world performance. AI that performs well in validation but degrades in deployment creates regulatory exposure.

Financial Services

Financial AI behavioral evaluation is governed primarily by SR 11-7's model risk management framework. Key requirements:

Independent validation. Model validation must be independent of model development. Self-validation (the development team also validates the model) is not acceptable under SR 11-7. This requirement drives the use of external evaluation services or separate internal validation teams.

Backtesting and stress testing. Financial models must be backtested against historical data and stress-tested against adverse scenarios. AI agents making financial recommendations must demonstrate robust performance during periods of market stress, not just normal conditions.

Champion-challenger testing. Before deploying a new AI model, it should be run in champion-challenger mode: the new model (challenger) runs against the same inputs as the production model (champion), and performance is compared. Widespread deployment happens only if the challenger demonstrably outperforms or matches the champion.

Documentation standards. SR 11-7 requires extensive model documentation: conceptual soundness description, data sources, validation procedures, ongoing monitoring approach, and limitations. Documentation must be sufficient for examiners to understand and assess the model.

Comparison

Healthcare evaluation prioritizes clinical validity and demographic equity; financial services evaluation prioritizes independence, rigor, and stress-testing. Both require ongoing monitoring, but the monitoring focus differs: healthcare monitors for patient outcome impacts; financial services monitors for economic performance and regulatory compliance.

Comparison Dimension 5: Oversight Requirements

Healthcare

Clinical AI oversight requirements are shaped by the principle that autonomous AI should not make final clinical decisions — a physician must be in the loop for consequential decisions.

Decision support, not decision replacement. FDA SaMD guidance and CMS (Centers for Medicare & Medicaid Services) policy both emphasize that AI in clinical settings should support clinical judgment, not replace it. AI agents that make autonomous clinical decisions without physician review face regulatory challenges.

Real-time monitoring for safety. For AI agents operating in clinical settings (patient interaction, medication management, monitoring), real-time safety monitoring is required. The healthcare standard is that any AI failure mode with potential for patient harm requires immediate detection and response.

Documentation in medical record. Clinical decisions influenced by AI should be documented in the medical record. If an AI agent's recommendation influenced a clinical decision, that influence should be reflected in the documentation.

Financial Services

Financial services oversight requirements vary by AI function:

Suitability review for advice. AI-generated investment recommendations must be reviewed for suitability before delivery to clients. The level of review depends on the recommendation's importance — fully automated delivery may be acceptable for low-stakes recommendations but is problematic for high-stakes ones.

Real-time monitoring for market manipulation. AI agents executing trades are subject to real-time monitoring for market manipulation patterns. FINRA and the SEC have sophisticated surveillance systems; broker-dealers running AI trading agents must also have real-time surveillance capable of detecting manipulation patterns.

Audit trail for compliance. All AI-influenced financial decisions must have audit trails sufficient for regulatory examination. Regulators have the ability to examine trading activity, customer communications, and advice records — AI activity must be captured in these records.

Comparison

Both domains require human oversight, but the oversight model differs significantly. Healthcare oversight focuses on the clinician retaining final decision authority; financial services oversight focuses more on audit trails and retrospective compliance verification than on real-time human approval for individual decisions. Healthcare has a lower tolerance for fully autonomous AI in high-consequence decisions; financial services allows more automation with strong audit controls.

Comparison Dimension 6: Adversarial Threat Models

Healthcare

Clinical AI faces adversarial threats that are less financially motivated than financial services but can have catastrophic physical consequences:

Adversarial attacks on clinical images. AI-based diagnostic imaging systems have been shown to be vulnerable to adversarial perturbations — small modifications to images that cause the AI to misclassify. In clinical settings, this could result in missed diagnoses or false positives.

Model poisoning in federated learning. Healthcare AI frequently uses federated learning across multiple hospital systems to train on distributed data without centralizing PHI. Federated learning is vulnerable to poisoning attacks where a participating hospital contributes malicious updates that compromise the global model.

Prompt injection for PHI exfiltration. AI agents with access to PHI are targets for prompt injection attacks designed to extract PHI through carefully constructed inputs. Healthcare AI must be defended against these attacks given the high sensitivity of the data.

Financial Services

Financial services adversarial threats are more financially motivated and often more sophisticated:

Adversarial inputs for regulatory evasion. AI compliance monitoring systems (AML, sanctions screening) face adversarial inputs specifically designed to evade detection — money laundering schemes structured to avoid triggering rules, communications designed to avoid keyword detection.

Market manipulation via AI-to-AI interaction. Trading AI systems interact with each other in market microstructure. Sophisticated adversaries can craft order flow patterns that exploit known behavior of market-making AI systems — a type of adversarial attack that operates through market mechanisms rather than direct system compromise.

Model reverse engineering for competitive advantage. Financial institutions have strong incentives to understand competitors' AI models — particularly trading models. Adversarial probing to infer model parameters creates a category of attack with no healthcare equivalent.

Comparison: Healthcare adversarial threats focus on data integrity and PHI exfiltration; financial services adversarial threats are more varied and include market-mechanism attacks with no healthcare parallel. Financial services adversaries are typically more sophisticated and better-resourced.

Comparison Dimensions 7 and 8: Incident Response and Certification

Incident Response

Healthcare: HIPAA Breach Notification Rule requires notification of affected individuals within 60 days of breach discovery; notification of HHS within 60 days; notification of media for breaches affecting 500+ individuals in a state. For SaMD failures, FDA Medical Device Reporting (MDR) requirements mandate reporting of deaths, serious injuries, and device malfunctions that could cause or contribute to harm.

Financial services: Financial institutions must notify primary federal regulators within 36 hours of a "notification incident" (bank computer security incidents that materially disrupt, degrade, or impair customer operations). Customer notification for fraud-related incidents generally follows state data breach notification laws. SEC requires public disclosure of material cybersecurity incidents within four business days of materiality determination.

Comparison: Financial services has faster notification requirements (36 hours vs. 60 days for HIPAA); healthcare has broader notification scope (all affected individuals vs. regulatory notification only for financial services).

Certification Paths

Healthcare: FDA 510(k) clearance or De Novo authorization for SaMD; HITRUST certification for health data security; Joint Commission accreditation requirements for healthcare facilities using AI.

Financial services: SR 11-7 model validation; ISO 20022 compliance for payment systems; DORA technical standards (EU); no single AI certification analogous to FDA clearance.

Comparison: Healthcare has a more defined pre-market certification pathway (FDA SaMD framework); financial services relies more on ongoing examination by regulators than on pre-market certification.

The Armalo Cross-Domain Approach

Armalo's trust infrastructure is designed to support domain-specific trust requirements without requiring organizations to build separate trust systems for each domain.

Domain-specific behavioral pact templates provide the contractual foundation for trust in each domain. Healthcare pacts include HIPAA minimum-necessary provisions, FDA SaMD documentation requirements, and clinical validation evidence specifications. Financial services pacts include SR 11-7 model validation requirements, suitability documentation, and real-time monitoring specifications.

Context-aware trust scoring applies different weighting to trust dimensions based on the deployment domain. Safety scores (11% weight in the composite) receive additional weighting in healthcare deployments where patient safety is the primary concern. Security scores (8% weight) receive additional weighting in financial services deployments where data integrity and information asymmetry control are paramount.

Domain-specific adversarial evaluation — using healthcare-relevant and financial-services-relevant attack taxonomies — ensures that the red-team evaluation is calibrated to the threats actually faced in each domain, not just the general adversarial threat model.

Memory attestations include domain context metadata, enabling accurate context translation when an agent's reputation crosses domain boundaries.

Conclusion: Different Domains, Common Foundation

Healthcare and financial services AI agents share a common trust foundation: behavioral evidence, cryptographic verifiability, human oversight, audit trails, and consequence mechanisms for violations. What differs are the specific requirements, the regulatory authorities that enforce them, the liability structures that create consequences, and the adversarial threat models that shape security design.

Organizations deploying AI agents in either domain — or both — need governance infrastructure that is simultaneously aligned with the common foundation and appropriately differentiated for the domain-specific requirements. One-size-fits-all trust frameworks fail because they either over-constrain low-risk deployments or under-constrain high-risk ones.

The comparative analysis developed here provides the vocabulary for those conversations: when a CISO trained in healthcare moves to a financial services company, or when a CTO tries to adapt a financial services AI governance framework for a healthcare acquisition, this map provides the orientation needed to identify where expertise transfers and where new learning is required.

Key Takeaways:

• Healthcare regulation is more prescriptive (FDA SaMD framework, HIPAA specific requirements); financial services is more principle-based (fiduciary duty, SR 11-7 guidance).
• Healthcare liability is filtered through clinical intermediaries; financial services liability is more direct (fiduciary duty claims, ECOA adverse action).
• Healthcare data governance focuses on PHI protection; financial services adds unique requirements for MNPI control and insider trading prevention.
• Healthcare oversight requires physician-in-the-loop for consequential decisions; financial services allows more automation with strong audit controls.
• Healthcare adversarial threats focus on diagnostic integrity and PHI extraction; financial services faces market-mechanism adversarial attacks with no healthcare parallel.
• Armalo's domain-specific pacts, context-aware scoring, and domain-calibrated evaluation support deployment across both domains without requiring separate trust systems.